Time filter

Source Type

Thessaloníki, Greece

Tsachouridou O.,Aristotle University of Thessaloniki | Christoforidou A.,Aristotle University of Thessaloniki | Metallidis S.,Aristotle University of Thessaloniki | Papaioannou M.,AHEPA Hospital | And 5 more authors.
European Archives of Oto-Rhino-Laryngology | Year: 2012

Objectives Plasmablastic lymphoma (PBL) of the oral cavity is a rare form of non-Hodgkin lymphoma that is most frequently met in human immunodeficiency (HIV) positive patients. Only a few cases have been reported worldwide since 1997. This clinical entity may escape detection due to its unusual immunophenotype and rare occurrence. Our aim is to present two cases with this rare condition that were diagnosed and treated in our department. Materials and methods We describe two cases of PBLs in HIV-infected patients, who presented with an expanding painless oral lesion and summarize the literature in order to elucidate the nature of this malignancy. Results The first patient received chemotherapy with additional radiotherapy that led to complete remission of the disease, while the second experienced a relapse 6 months after treatment with chemotherapy, that caused his death after refusal of further treatment. Conclusion Because of the consistent epidemiological association of PBL with immunosuppression, any patient diagnosed with PBL should be tested for HIV. The clinical picture of PBL, including its affinity with HIV-infection, male sex, and its predilection for the oral cavity, may contribute to the differential diagnosis. Any oral mass occurring in an immunosuppressed patient should be referred for biopsy, since the early diagnosis of these tumors leads to better prognosis of the patients. © Springer-Verlag 2012. Source

Ritch R.,Einhorn Clinical Research Center | Ritch R.,New York Medical College | Prata T.S.,Einhorn Clinical Research Center | De Moraes C.G.V.,Einhorn Clinical Research Center | And 5 more authors.
Acta Ophthalmologica | Year: 2010

Purpose: To evaluate prospectively the frequency with which exfoliation syndrome (XFS) occurs in patients with central retinal vein occlusion (CRVO) by clinical examination and ultrastructural examination of conjunctival biopsy specimens. Methods: Prospective observational case series. Thirty-six eyes of 36 consecutive patients with CRVO were investigated for XFS by slit-lamp examination and conjunctival biopsy when XFS was not clinically visible on examination. Results: A clinical diagnosis of XFS or a positive biopsy result for exfoliation material (XFM) was present in 22 of the 36 patients (61%; 95% confidence interval 45-75%). Twelve of these 22 patients (54%) had a clinical diagnosis of XFS. Aggregates of XFM were identified ultrastructurally in the biopsy specimens in 10 of 24 patients with no clinical signs of XFS (42%). Patients with and without XFS had similar distribution of age, gender, race and prevalence of systemic disorders. Twelve of the 22 (54%) XFS patients had neither glaucoma nor ocular hypertension prior to the CRVO. Conclusion: In accordance with previous retrospective and histological studies, this prospective, in vivo study suggests that CRVO is commonly associated with XFS. © 2009 Acta Ophthalmol. Source

Panidis D.,Aristotle University of Thessaloniki | Tziomalos K.,AHEPA Hospital | MacUt D.,University of Belgrade | Kandaraki E.A.,Aristotle University of Thessaloniki | And 3 more authors.
Gynecological Endocrinology | Year: 2013

Aim: To compare the prevalence of metabolic syndrome (MetS) between women with polycystic ovary syndrome (PCOS) and controls across different age (20, 21-30 and 31-39 years old) and body mass index (BMI) (normal weight, overweight and obese) groups. Methods: We studied 1223 women with PCOS and 277 BMI-matched controls. The prevalence of MetS in women with PCOS and controls was estimated according to four different MetS definitions. Results: In subjects 20 and 21-30 years old, the prevalence of MetS did not differ between women with PCOS and controls regardless of the MetS definition, even though women with PCOS were more obese than controls in the 20 years old group. In subjects 31-39 years old, the prevalence of MetS was higher in women with PCOS than in controls but the former were more obese than controls. The prevalence of MetS did not differ significantly between women with PCOS and controls in any of the BMI groups (normal weight, overweight or obese) regardless of the MetS definition. Conclusion: The prevalence of Mets appears to be primarily determined by obesity and age whereas PCOS per se appears to be a less important contributing factor. © 2013 Informa UK Ltd. Source

Kouparanis A.,AHEPA Hospital | Bozikas A.,AHEPA Hospital | Spilioti M.,Aristotle University of Thessaloniki | Tziomalos K.,AHEPA Hospital
Brain Injury | Year: 2015

Background: Neuroleptic malignant syndrome (NMS) is a rare life-threatening disorder resulting from treatment with neuroleptic agents and other drugs that act as dopamine antagonists. NMS most often occurs shortly after the initiation, dose increase or withdrawal of the offending agent, but can rarely occur after long-term treatment at stable doses. Immediate discontinuation of the causative agent (or re-Administration if the cause is the withdrawal of neuroleptic therapy) along with supportive therapy to maintain cardiorespiratory stability and to reduce fever are the cornerstone of the management of NMS. Additional 'specific' treatments include dantrolene, bromocriptine and amantadine, but their role in the management of NMS is controversial. Case study: This study reports the case of NMS associated with long-term treatment with olanzapine at a stable dose. Administration of dantrolene was well-tolerated and resulted in prompt resolution of NMS symptoms. © 2015 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted. Source

Karlafti E.F.,AHEPA Hospital | Hatzitolios A.I.,AHEPA Hospital | Karlaftis A.F.,National and Kapodistrian University of Athens | Baltatzi M.S.,AHEPA Hospital | And 2 more authors.
Journal of Pharmacy and Bioallied Sciences | Year: 2013

Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys. Source

Discover hidden collaborations